WO2011126957A1 - Procédé pour la purification de trypsine et de chymotrypsine au moyen d'une chromatographie d'interactions hydrophobes - Google Patents

Procédé pour la purification de trypsine et de chymotrypsine au moyen d'une chromatographie d'interactions hydrophobes Download PDF

Info

Publication number
WO2011126957A1
WO2011126957A1 PCT/US2011/031036 US2011031036W WO2011126957A1 WO 2011126957 A1 WO2011126957 A1 WO 2011126957A1 US 2011031036 W US2011031036 W US 2011031036W WO 2011126957 A1 WO2011126957 A1 WO 2011126957A1
Authority
WO
WIPO (PCT)
Prior art keywords
trypsin
chymotrypsin
media
groups
hydrophobic interaction
Prior art date
Application number
PCT/US2011/031036
Other languages
English (en)
Inventor
Bhaktavachalam Thiyagarajan
Steve Magee
Nandu Deorkar
Original Assignee
Avantor Performance Materials, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avantor Performance Materials, Inc. filed Critical Avantor Performance Materials, Inc.
Publication of WO2011126957A1 publication Critical patent/WO2011126957A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)

Definitions

  • the invention relates to the use of chromatographic media for the separation and purification of proteins. More particularly, the current invention discloses use of hydrophobic chromatographic media for the separation and purification of closely related proteolytic enzymes trypsin and chymotrypsin.
  • the manufacturing process provided in this invention is intended for separation of mixture of serine proteases such as trypsin and chymotrypsin from their contaminants using hydrophobic chromatography commonly referred to as HIC (Hydrophobic Interaction Chromatography). Further more, the process also provides viral clearance (removal) for trypsin and chymotrypsin.
  • HIC Hydrophobic Interaction Chromatography
  • Trypsin and chymotrypsin are members of the serine proteases family.
  • trypsin acts with the other proteinases to break down dietary proteins molecules to their component peptides and amino acids. Trypsin continues the process of digestion, begun in the stomach, in the small intestines where a slightly alkaline environment, about pH 8, promotes its maximal enzymatic activity. Trypsin, produced in an inactive form by the pancreas, is remarkably similar in chemical composition and in structure to the other chief pancreatic proteinase, chymotrypsin.
  • trypsin and chymotrypsin molecules appear to be their specificity, that is, each is active only against the C- terminal ends of peptide bonds in protein molecules that have carboxyl groups donated by certain amino acids.
  • trypsin those amino acids are arginine and lysine, except when either is followed by proline; for chymotrypsin, which recognizes aromatic residues, those amino acids are tyrosine, phenylalanine, tryptophan, methionine and leucine., while trypsin recognizes lysine and arginine.
  • Trypsin is the most discriminating of all the proteolytic enzymes in terms of the restricted number of chemical bonds that it will attack. Good use of this fact has been made by chemists interested in the determination of the amino acid sequence of proteins. Trypsin is widely employed as a reagent for the orderly and unambiguous cleavage of such molecules. The process is commonly referred to as protein proteolysis or trypsination and protein that have been digested/treated with trypsin is said to have been trypsinized.
  • trypsin and chymotrypsin are extracted from pancreas and pancreatic juices of various animals including bovine and porcine pancreas and pancreatic juices. They are generally isolated using multiple precipitation, fractionation, and filtration steps. Because of the similarity between trypsin and chymotrypsin structures and similar physicochemical properties, commercial sources of trypsin almost always contains significant amount of chymotrypsin and vice versa.
  • the purification of trypsin can be performed by a number of methods including but not limited to ammonium sulfate precipitation, ion-exchange chromatography and affinity chromatography.
  • purified trypsin contains varying amount of chymotrypsin. There is therefore a need for a process for producing trypsin with an insignificant, minimal or non-detectable amount of chymotrypsin.
  • mammalian-derived trypsin may contain adventitious agents, such as viruses that are detrimental for the final use of the trypsin or chymotrypsin.
  • adventitious agents such as viruses that are detrimental for the final use of the trypsin or chymotrypsin.
  • This invention relates to a method of separating the biologically active compounds trypsin and chymotrypsin upon selective adsorbents using hydrophobic interaction chromatographic media.
  • a method for the separation and purification of trypsin and chymotrypsin comprising contacting a crude mixture of trypsin and chymotrypsin with a hydrophobic interaction chromatography media wherein the method comprises passing the crude mixture through a hydrophobic chromatographic media whereby chymotrypsin is bound to the hydrophobic chromatographic media and trypsin passes through the media without binding to said media to produce purified trypsin, and thereafter bound chymotrypsin is eluted from the media to produce purified chymotrypsin.
  • Hydrophobic interaction chromatography differs from reversed-phase HPLC in that the latter requires strong organic solvent to elute the molecules, whereas HIC usually operates using aqueous buffers and binding and elution of the solute molecules tuned by salt concentration.
  • Hydrophobic interaction chromatography utilizes the interaction between the hydrophobic surface of the chromatographic media and the hydrophobic groups on the proteins molecules. This interaction is strongly influenced by the presence of certain salts. A high salt concentration of certain salts from about 0.8 M to about 1.5 M generally increases the interaction between the proteins and the hydrophobic surface and a low salt concentration decreases the interaction.
  • the process is conducted employing a hydrophobic interaction chromatographic media having both hydrophobic groups and weak anion exchange functionality.
  • hydrophobic interaction chromatographic media having alkyl, alkanoyl, phenyl, benzoyl, phenylalkyl or phenylalkanoyl functional groups. More particularly, hydrophobic interaction chromatographic mixed mode media having hydrophobic groups such as alkyl, alkanoyl, phenyl, benzoyl, phenylalkyl or phenylalkanoyl functional groups along with weak anion exchange functionality are preferred.
  • chymotrypsin is bound to the hydrophobic interaction chromatographic media and trypsin passes through the media without binding to said media under high salt conditions of from about 0.8M to about 1.5M.
  • the hydrophobic media could be one of several commercially available media such as butyl Sepharose, octyl Sepharose, phenyl Sepharose from GE Healthcare or Toyopearl butyl, Toyopearl phenyl, Toyopearl hexyl from Tosoh Bioscience LLC.
  • the media is a hydrophobic interaction chromatographic mixed mode media having alkyl, alkanoyl, phenyl, benzoyl, phenalkyl or phenylalkanoyl functional groups attached to some of the polyethyleneimine ligands on a polymeric surface of a polymeric or inorganic chromatographic media.
  • the non-functionalized polyethyleneimine groups covalently attached on the polymeric surface or inorganic materials provide weak anion exchange sites.
  • the polymeric media may be based on any suitable natural or synthetic polymers, such as for example, agarose, polymethacrylate, and polystyrene.
  • Inorganic media may be based on titanium dioxide, zirconium dioxide, or silica.
  • the alkyl or alkanoyl groups of the alkyl, alkanoyl, phenylalkyl or phenylalkanoyl functional groups can have from 1 to 8 carbon atoms, preferably 1 to 4, more preferably 1 to 3, carbon atoms in the alkyl or alkanoyl groups.
  • Such hydrophobic chromatographic media may be purchased from the aforementioned suppliers and the mixed mode hydrophobic chromatographic media based on polyethyleneimine covalently attached on the surface of polymers, particularly polymethacrylate polymers, or inorganic media, particularly silica gel, may be prepared according to the disclosures in US Patent Application Publication No. US20080203029 and US Patent 4, 551, 245, which documents are incorporated herein by reference thereto.
  • the mixed mode hydrophobic media are commercially available from JT Baker under the product number 7588 for polymethacrylate based material and 7182 for silica based material.
  • the use of the hydrophobic interaction chromatographic media in the invention process enables running the purification process at lower pH ( ⁇ 3) and this lower pH is known to inactivate viruses.
  • Fig. 1 is a graph of USP units/ml versus fraction number for the purification process exemplified in Example 1.
  • Fig. 2 is a graph of USP units/ml versus fraction number for the purification process exemplified in Example 2.
  • Fig. 3 is a graph of USP units/ml versus fraction number for the purification process exemplified in Example 3.
  • Fig. 4 is a graph of USP units/ml versus fraction number for the purification process exemplified in Example 4.
  • Fig. 5 is a graph of USP units/ml versus fraction number for the purification process exemplified in Example 5.
  • Fig. 6 is a graph of USP units/ml versus fraction number for the purification process exemplified in Example 6.
  • This invention relates to a method of separating biologically active compounds trypsin and chymotrypsin upon selective adsorbents using mixed mode having weak anion and hydrophobic (reverse phase) functional groups.
  • One aspect of the invention comprises a method for the separation and purification of trypsin and chymotrypsin comprising contacting a crude mixture of trypsin and chymotrypsin with a hydrophobic interaction chromatography media, more preferably a mixed mode hydrophobic interaction chromatographic media, in a chromatographic column, wherein the hydrophobic interaction chromatographic media is preferably a hydrophobic interaction chromatographic mixed mode media having weak anion exchange functionality and alkyl, alkanoyl, phenyl, benzoyl, phenylalkyl or phenylalkanoyl hydrophobic functional groups, whereby chymotrypsin is bound to the chromatographic media and trypsin passes through the media without binding to said media to produce purified trypsin, and thereafter bound chymotrypsin is eluted from the media to produce purified chymotrypsin.
  • a hydrophobic interaction chromatography media more preferably a mixed mode hydrophobic interaction
  • Another aspect of the invention comprises the method wherein the bound chymotrypsin is eluted from the chromatographic media under low salt conditions, i.e., containing less than about 50 to lOOmM commonly used salts, such as for examples acetates or sulfates and the like.
  • the crude mixture is passed through the hydrophobic interaction chromatographic media under high salt conditions of from about 0.8 M to about 1.5 M salt and the bound chymotrypsin is eluted from the hydrophobic interaction chromatographic media under low salt conditions of from about 50 to about 100 mM salt.
  • Another aspect of the invention comprises the method wherein mixed mode hydrophobic interaction chromatographic media is one having alkyl, alkanoyl, phenyl, benzoyl, phenylalkyl or phenylalkanoyl groups attached to polyethyleneimine ligands on a polymeric surface of a polymeric polymethacrylate media or silica gel media.
  • Another aspect of the invention comprises the method wherein the polymeric surface comprises a polymethacrylate polymeric surface and the alkyl, alkanoyl, phenylalkyl and phenylalkanoyl groups have from 1 to 8 carbon atoms in the alkyl or alkanoyl groups.
  • Another aspect of the invention comprises the method wherein the alkanoyl groups and phenylalkanoyl groups have from 1 to 4, more preferably 1 to 3, carbon atoms in the alkanoyl groups.
  • Another aspect of the invention comprises the method wherein the hydrophobic functional groups are propanoyl groups.
  • Another aspect of the invention comprises the method wherein the hydrophobic functional groups are butanoyl groups.
  • Another aspect of the invention comprises the method wherein the hydrophobic functional groups are phenylpropanoyl groups.
  • Another aspect of the invention comprises the method wherein the hydrophobic functional groups are phenylbutanoyl groups
  • Another aspect of the invention comprises the method wherein the bound chymotrypsin is eluted with acetic acid.
  • Another aspect of the invention comprises the method wherein the crude mixture is contacted with the hydrophobic interaction chromatographic media as a pH 3 solution of the crude mixture with ammonium sulfate.
  • Another aspect of the invention comprises the method wherein the flow throughpurified trypsin is freeze-dried to a semi-crystalline powder.
  • Another aspect of the invention comprises the method wherein the purified trypsin has a trypsin activity of 3500 USP units/mg or greater and a trypsin/chymotrypsin activity ratio of more than 50.
  • Example 1 171.8 g of ammonium sulfate was dissolved in 800 mL 50 mM acetic acid and the pH was adjusted to 3.0 with sulfuric acid. The solution was diluted to 1 L with 50 mM acetic acid to give 1.3 M ammonium sulfate at pH 3.0. 20 g crude trypsin containing 1775 USP units/mg with the trypsin/Chymotrypsin activity ratio being 8.2 was dissolved in 2L of 1.3 M ammonium sulfate at pH 3.0 to give 10 mg/mL solution.
  • the solution was filtered and loaded, at the flow rate of 50 mL/min (150 cm/hr) on to a column of dimension (5.0 cm ID and 200 mL volume) loaded with a chromatographic media of a polymethacrylate polymer having polyethyleneimine ligand bound to the surface thereof and functionalized with hydrophobic propanoyl groups produced according to Example 19 of US Patent Application Publication No. US20080203029.
  • the column was then washed with 600 ml (3 column volumes (CV)) of 1.3 M ammonium sulfate at pH 3.0 and then eluted with step gradient (4 CV) to 35 % elution buffer of 50 mM acetic acid followed by linear gradient to 100 % 50 mM acetic acid (8 CV).
  • the fractions were analyzed for Trypsin and Chymotrypsin activity using US Pharmacpoeia method (USP Monographs, 3823- 3824, USP 32, Volume-Ill, 2009) and shown in the Figure 1 and the fractions with higher trypsin content were combined and desalted and freeze-dried to get a pure form of trypsin.
  • the lyophilized pool contains 3500 USP units of trypsin/mg with the trypsin/chymotrypsin activity ratio being 86.
  • A280 is the total absorbance at 280 namometers.
  • Example 2 28.1 g of crude trypsin containing 2795 USP units/mg with the trypsin/Chymotrypsin activity ratio being 8 was dissolved in 562 mL of 0.25 % (w/w) sulfuric acid and the pH was adjusted to 3 with concentrated ammonium hydroxide. 562 mL of 2.5 M ammonium sulfate in 100 mM acetic acid was added to the solution to bring the trypsin concentration of 25 mg/ml at pH 3 with 1.25 M ammonium sulfate. About 10 grams of celite was added to the solution and the solution was filtered through a 0.45 micron filter.
  • the resulting clear solution was then loaded, at the flow rate of 50 mL/min (150 cm/hr), onto a column (5cm diameter, 200mL) containing the mixed mode media of the type employed in Example 1. After the loading the column was washed with 3 CV of 1.25 M ammonium sulfate, pH 3 and eluted with 50 mM acetic acid with 4 CV.
  • the fractions were analyzed for trypsin and chymotrypsin activity using US Pharmacopoeia method (USP Monographs, 3823-3824, USP 32, Volume-Ill, 2009) and are shown in the Figure 2.
  • A280 is t he total absorbance at 280 namometers. The fractions with higher trypsin content were combined and desalted and freeze-dried to provide a purified form of trypsin having a trypsin/chymotrypsin activity ratio of 48.
  • Example 3 22.4 g of crude trypsin containing 3022 USP units/mg trypsin was dissolved in 560 mL of 0.25 % (w/w) sulfuric acid and the pH was adjusted to 3 with concentrated ammonium hydroxide. 560 mL of 2.6 M ammonium sulfate in 100 mM acetic acid was added to the solution to bring the trypsin concentration of 20 mg/ml at pH 3 with 1.3 M ammonium sulfate. About 10 grams of celite was added to the solution and the solution was filtered through a 0.45 micron filter.
  • the resulting clear solution containing trypsin to chymotrypsin activity ratio of approximately 6 was then loaded, at the flow rate of 50 mL/min (150 cm/hr), onto a column (5cm diameter, 200mL) packed with the media as employed in Example 1 After the loading the column was washed with 3 CV of 1.25 M ammonium sulfate, pH 3 and eluted with 50 mM acetic acid with 4 CV. The fractions were analyzed for trypsin and chymotrypsin activity using the US Pharmacopedia method (USP Monographs, 3823-3824, USP 32, Volume-Ill, 2009) and are shown in Fig. 3.
  • A280 is the total absorbance at 280 namometers.
  • the fractions with higher trypsin content were combined and desalted and freeze-dried to get a purified form of trypsin with an activity of higher than 3500 USP units/mg.
  • the trypsin/chymotrypsin activity increased from 11 to 69 for the collected pool that contains purified trypsin activity of 3500 UPS units/ml.
  • Example 4 1.68 g of crude trypsin containing 3022 USP units of trypsin/mg was dissolved in 42 mL of 0.25 % (w/w) sulfuric acid and the pH was adjusted to 3 with concentrated ammonium hydroxide. 42 mL of 2.6 M ammonium sulfate in 100 mM acetic acid was added to the solution to bring the trypsin concentration of 20 mg/ml at pH 3 with 1.3 M ammonium sulfate. About 2 grams of celite was added to the solution and the solution was filtered through 0.45 micron filter.
  • the resulting clear solution was then loaded onto a column (1cm diameter, 7.8 mL) at the flow rate of 1.8 mL/min (140 cm/hr).
  • the column contained a mixed mode media comprising polymethacrylate polymer having polyethyleneimine ligand bound to the surface thereof and functionalized with hydrophobic butanoyl groups, prepared according to process described in Example 19 of US Patent Application Publication No. US20080203029 with substitution of valeric anhydride for butyric anhydride reactant.
  • the column was washed with 3 CV of 1.25 M ammonium sulfate, pH 3 and eluted with 50 mM acetic acid with 4 CV.
  • the fractions were analyzed for trypsin and chymotrypsin activity using the US Pharmacopedia method (USP Monographs, 3823-3824, USP 32, Volume-Ill, 2009) and are shown in Fig. 4.
  • A280 is the total absorbance at 280 namometers.
  • the fractions with higher trypsin content were combined and desalted and freeze-dried to get a purified form of trypsin.
  • the trypsin/chymotrypsin activity ratio increased from 2.4 to 82 for the fraction that contains the purified form of trypsin having more than 3500 USP trypsin units /mL.
  • Example 5 1.68 g of crude trypsin containing 3022 USP units of trypsin/mg was dissolved in 42 mL of 0.25 % (w/w) sulfuric acid and the pH was adjusted to 3 with concentrated ammonium hydroxide. 42 mL of 2.6 M ammonium sulfate in 100 mM acetic acid which was adjusted to pH 3 with sulfuric acid was added to the solution to bring the trypsin concentration of 20 mg/ml at pH 3 with 1.3 M ammonium sulfate. About 2 grams of celite was added to the solution and the solution was filtered through 0.45 micron filter.
  • the resulting clear solution was then loaded, at the flow rate of 1.8 mL/min (140 cm/hr), onto a column (1cm diameter, 7.8 mL).
  • the column contained a mixed mode media comprising polymethacrylate polymer having polyethyleneimine ligand bound to the surface thereof and functionalized with hydrophobic phenoyl groups, prepared according to process described in Example 19 of US Patent Application Publication No. US20080203029 with substitution of benzoic anhydride for butyric anhydride reactant.
  • the column was washed with 3 CV of 1.25 M ammonium sulfate, pH 3 and eluted with 50 mM acetic acid with 4 CV.
  • the fractions were analyzed for trypsin and chymotrypsin activity using the US Pharmacopedia method (USP Monographs, 3823-3824, USP 32, Volume-Ill, 2009) and are shown in Fig. 5.
  • A280 is the total absorbance at 280 namometers.
  • the fractions with higher trypsin content were combined and desalted and freeze- dried to get a purified form of trypsin.
  • the trypsin/chymotrypsin activity ratio was increased from 6 to more than 50 for the pool of purified trypsin that contains more than 3500USP trypsin units/mg.
  • Example 6 1.60 g of crude trypsin containing 3022 USP units trypsin/mg was dissolved in 40 mL of 0.25 % (w/w) sulfuric acid and the pH was adjusted to 3 with concentrated ammonium hydroxide. 40 mL of 2.6 M ammonium sulfate in 100 mM acetic acid was added to the solution to bring the trypsin concentration of 20 mg/ml at pH 3 with 1.3 M ammonium sulfate. About 2 grams of celite was added to the solution and the solution was filtered through a 0.45 micron filter.
  • the resulting clear solution was then loaded, at the flow rate of 1.8 mL/min (140 cm/hr), onto a column (1cm diameter, 7.8 mL).
  • the column contained a mixed mode media comprising polymethacrylate polymer having polyethyleneimine ligand bound to the surface thereof and functionalized with hydrophobic phenylpropanoyl groups, prepared according to process described in Example 19 of US Patent Application Publication No. US20080203029 with substitution of to the benzoic anhydride for butyric anhydride reactant.
  • the column was washed with 3 CV of 1.25 M ammonium sulfate, pH 3 and eluted with 50 mM acetic acid with 4 CV.
  • the fractions were analyzed for trypsin and chymotrypsin activity using the US Pharmacopedia method (USP Monographs, 3823-3824, USP 32, Volume-Ill, 2009) and are shown in Fig. 6.
  • A280 is the total absorbance at 280 nanometers.
  • the fractions with higher trypsin content were combined and desalted and freeze-dried to get a purified form of trypsin.
  • the trypsin/chymotrypsin activity ratio was increased from 5 to more than 50 for the pool that contains the purified trypsin having more than 3500 USP trypsin units/mg.
  • Example 7 1.60 g of crude trypsin containing 3022 USP units trypsin/mg is dissolved in 40 mL of 0.25 % (w/w) sulfuric acid and the pH is adjusted to 3 with concentrated ammonium hydroxide. 40 mL of 2.6 M ammonium sulfate in 100 mM acetic acid is added to the solution to bring the trypsin concentration to 20 mg/ml at pH 3 with 1.3 M ammonium sulfate. About 2 grams of celite is added to the solution and the solution is filtered through a 0.45 micron filter to produce a crude solution containing 20 mg/mL crude trypsin/chymotrypsin.
  • This crude trypsin solution is purified by processing through a 1 cm diameter column with a column volume of 7.8 mL packed with the hydrophobic media Toyopearl Butyl 650S from Tosoh Bioscience LLC, Montgomeryville, PA.
  • the crude trypsin is processed through the column at a flow rate of about 1.8 mL/min. After the column loading is complete the elution is completed using 59 mM acetic acid after the column is washed with 1.25M ammonium sulfate at pH 3.
  • the resulting flow through fraction will contain more than 3500 USP trypsin units/mg and the trypsin/chymotrypsin activity ratio will increase from 5 to about 50.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de séparation et de purification de trypsine et de chymotrypsine, dans lequel un mélange brut de trypsine et de chymotrypsine est amené à passer sur un milieu de chromatographie d'interactions hydrophobes dans une colonne chromatographique. Le milieu de chromatographie d'interactions hydrophobes est de préférence un milieu pourvu d'une fonction d'échange d'anions faibles et de groupes fonctionnels alkyle, alcanoyle, phényle, benzoyle, phenylalkyle ou phénylalcanoyle, de telle sorte que la chymotrypsine se lie au milieu de chromatographie d'interactions hydrophobes chromatographique et que la trypsine passe sur le milieu sans se lier audit milieu pour produire de la trypsine purifiée, et ensuite, la chymotrypsine liée est éluée du milieu pour produire de la chymotrypsine purifiée.
PCT/US2011/031036 2010-04-05 2011-04-04 Procédé pour la purification de trypsine et de chymotrypsine au moyen d'une chromatographie d'interactions hydrophobes WO2011126957A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32084810P 2010-04-05 2010-04-05
US61/320,848 2010-04-05

Publications (1)

Publication Number Publication Date
WO2011126957A1 true WO2011126957A1 (fr) 2011-10-13

Family

ID=44144880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/031036 WO2011126957A1 (fr) 2010-04-05 2011-04-04 Procédé pour la purification de trypsine et de chymotrypsine au moyen d'une chromatographie d'interactions hydrophobes

Country Status (2)

Country Link
TW (1) TW201138974A (fr)
WO (1) WO2011126957A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104419695A (zh) * 2013-08-22 2015-03-18 上海亨臻实业有限公司 糜蛋白酶原的仿生亲和材料的制备及糜蛋白酶纯化方法
CN105368810A (zh) * 2015-11-25 2016-03-02 青岛康原药业有限公司 一种制备胰凝乳蛋白酶的方法
CN105400766A (zh) * 2015-11-21 2016-03-16 青岛康原药业有限公司 一种糜蛋白酶的制备方法及提高糜蛋白酶复溶性的药物组合物
CN105400764A (zh) * 2015-11-21 2016-03-16 青岛康原药业有限公司 一种亲和层析分段洗脱纯化糜蛋白酶的方法及提高糜蛋白酶稳定性的药物组合物
WO2020229145A1 (fr) * 2019-05-13 2020-11-19 Bioseutica B.V. Protéases de poisson purifiées ayant des activités spécifiques élevées et leur procédé de production

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551245A (en) 1985-04-22 1985-11-05 J. T. Baker Chemical Co. Acylated polyethylenimine bound chromatographic packing
WO2007064281A1 (fr) * 2005-12-02 2007-06-07 Ge Healthcare Bio-Sciences Ab Chromatographie d'interaction hydrophobe
US20080203029A1 (en) 2005-01-25 2008-08-28 Nandu Deorkar Chromatographic Media

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551245A (en) 1985-04-22 1985-11-05 J. T. Baker Chemical Co. Acylated polyethylenimine bound chromatographic packing
US20080203029A1 (en) 2005-01-25 2008-08-28 Nandu Deorkar Chromatographic Media
WO2007064281A1 (fr) * 2005-12-02 2007-06-07 Ge Healthcare Bio-Sciences Ab Chromatographie d'interaction hydrophobe

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG S ET AL: "Separation and Purification of Porcine PAncreatic Enzymes by Serial Operation of Ion-Exchange and Affinity Columns", CHROMATOGRAPHIA, VIEWEG UND TEUBNER VERLAG, DE, vol. 27, no. 9-10, 1 May 1989 (1989-05-01), pages 449 - 454, XP007918990, ISSN: 0009-5893 *
LAAS ET AL: "Agar derivatives for chromatography, electrophoresis and gel-bound enzymes", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V, NL, vol. 111, no. 2, 3 September 1975 (1975-09-03), pages 373 - 387, XP026484409, ISSN: 0021-9673, [retrieved on 19750903], DOI: DOI:10.1016/S0021-9673(00)99287-2 *
RAAE A J ET AL: "Purification and characterization of chymotrypsin, trypsin and elastase like proteinases from cod (Gadus morhua L.)", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. B. COMPARATIVEBIOCHEMISTRY, PERGAMON PRESS, LONDON, GB, vol. 93, no. 2, 1 January 1989 (1989-01-01), pages 317 - 324, XP023525767, ISSN: 0305-0491, [retrieved on 19890101] *
STROP P ET AL: "Model study of hydrophobic interactions of alpha- and beta-trypsin and alpha-chymotrypsin", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V, NL, vol. 259, 1 January 1983 (1983-01-01), pages 255 - 268, XP026551184, ISSN: 0021-9673, [retrieved on 19830101], DOI: DOI:10.1016/S0021-9673(01)88006-7 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104419695A (zh) * 2013-08-22 2015-03-18 上海亨臻实业有限公司 糜蛋白酶原的仿生亲和材料的制备及糜蛋白酶纯化方法
CN104419695B (zh) * 2013-08-22 2019-11-15 上海亨臻实业有限公司 糜蛋白酶原的仿生亲和材料的制备及糜蛋白酶纯化方法
CN105400766A (zh) * 2015-11-21 2016-03-16 青岛康原药业有限公司 一种糜蛋白酶的制备方法及提高糜蛋白酶复溶性的药物组合物
CN105400764A (zh) * 2015-11-21 2016-03-16 青岛康原药业有限公司 一种亲和层析分段洗脱纯化糜蛋白酶的方法及提高糜蛋白酶稳定性的药物组合物
CN105368810A (zh) * 2015-11-25 2016-03-02 青岛康原药业有限公司 一种制备胰凝乳蛋白酶的方法
WO2020229145A1 (fr) * 2019-05-13 2020-11-19 Bioseutica B.V. Protéases de poisson purifiées ayant des activités spécifiques élevées et leur procédé de production

Also Published As

Publication number Publication date
TW201138974A (en) 2011-11-16

Similar Documents

Publication Publication Date Title
Gaberc-Porekar et al. Perspectives of immobilized-metal affinity chromatography
EP2871968B1 (fr) Isolats de protéines de pomme de terre
WO2011126957A1 (fr) Procédé pour la purification de trypsine et de chymotrypsine au moyen d'une chromatographie d'interactions hydrophobes
ZA200608475B (en) Method for the purification of albumin conjugates
AU2011234521B2 (en) A process for purifying Vitamin K dependent proteins such as coagulation factor IX
AU2015207472B2 (en) A process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII:Ag
JP4250769B2 (ja) 高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法
CN105777862A (zh) 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子
Roy et al. Current trends in affinity-based separations of proteins/enzymes
Ishihara et al. Innovative next-generation monoclonal antibody purification using activated carbon: A challenge for flow-through and column-free processes
JP6713479B2 (ja) トロンビン及びその分解ポリペプチドの精製及び定量化方法
CN103328000A (zh) 用于从含有凝血因子的溶液中减少和/或除去FXI和FXIa的方法
CA2608281A1 (fr) Nouvelle methode de purification de la lactoferrine
MXPA06014318A (es) Proceso para aislamiento de proteinas.
EP2572190B1 (fr) Procédé de chromatographie d'interactions hydrophobes
AU4404597A (en) Process for isolating high purity glycomacropeptide from dairy products
STOFFEL et al. Analysis of the primary structure of the strongly hydrophobic brain myelin proteolipid apoprotein (lipophilin). Isolation and amino acid sequence determination of proteolytic fragments
de Aquino et al. Evaluation of IDA-PEVA hollow fiber membrane metal ion affinity chromatography for purification of a histidine-tagged human proinsulin
US5688912A (en) Peptide ligands which bind to von willebrand factor
JP2010145240A (ja) 疎水性アミノ酸又はアミノメチル安息香酸を固定化した液体クロマトグラフィー用充填剤、及びそれを用いた生体高分子の分離精製乃至捕集回収方法
WO1995004077A1 (fr) Procede de purification du plasminogene
Reifsnyder et al. Purification of insulin-like growth factor-I and related proteins using underivatized silica
US20110053225A1 (en) Multifunctional tags
Froidevaux et al. Continuous preparation of two opioïd peptides and recycling of organic solvent using liquid/liquid extraction coupled with aluminium oxide column during haemoglobin hydrolysis by immobilized pepsin
JP7230115B2 (ja) 翻訳後修飾α－トロンビン

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11716340

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11716340

Country of ref document: EP

Kind code of ref document: A1